OR WAIT null SECS
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Validating computerized systems is required to demonstrate adherence to data integrity, says Susan J. Schniepp, distinguished fellow at Nelson Laboratories, LLC.
Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. ecosystem.
January 03, 2024
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
A thoughtfully constructed QRM Master Plan translates the strategy and enables a risk-based approach.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
Analytical methods and tools play a pivotal role in cleaning validation.
The EHDS aims to increase access to health data, but how will it impact pharma?
Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.
December 29, 2023
Clinician-Scientists are vital innovation spark plugs, accounting for 40% of Nobel awards in Physiology or Medicine, and two thirds of Big Pharma CSOs.
December 27, 2023
The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.
December 26, 2023
WHO provides a look at the world’s health as the agency turns 75.
December 21, 2023
The final guidance document provides recommendations for designing a new registry or using an existing registry to support decisions regarding safety and effectiveness of a drug.